A Bionic Coulomb Phase on the Pyrochlore Lattice

A class of three dimensional classical lattice systems with macroscopic ground state degeneracies, most famously the spin ice system, are known to exhibit "Coulomb" phases wherein long wavelength correlations within the ground state manifold are described by an emergent Maxwell electrodynamics. We discuss a new example of this phenomenon-the four state Potts model on the pyrochlore lattice-where the long wavelength description now involves three independent gauge fields as we confirm via simulation. The excitations above the ground state manifold are bions, defects that are simultaneously charged under two of the three gauge fields, and exhibit an entropic interaction dictated by these charges. We also show that the distribution of flux loops shows a scaling with loop length and system size previously identified as characteristic of Coulomb phases

Prethermalization without Temperature

While a clean, driven system generically absorbs energy until it reaches "infinite temperature," it may do so very slowly exhibiting what is known as a prethermal regime. Here, we show that the emergence of an additional approximately conserved quantity in a periodically driven (Floquet) system can give rise to an analogous long-lived regime. This can allow for nontrivial dynamics, even from initial states that are at a high or infinite temperature with respect to an effective Hamiltonian governing the prethermal dynamics. We present concrete settings with such a prethernial regime, one with a period-doubled (time-crystalline) response. We also present a direct diagnostic to distinguish this prethermal phenomenon from its infinitely long-lived many-body localized cousin. We apply these insights to a model of the recent NMR experiments by Rovny et al. [Phys. Rev. Lett. 120, 180603 (2018)] which, intriguingly, detected signatures of a Floquet time crystal in a clean three-dimensional material. We show that a mild but subtle variation of their driving protocol can increase the lifetime of the time-crystalline signal by orders of magnitude

Numerical Investigation of Monopole Chains

We present numerical results for chains of SU(2) BPS monopoles constructed from Nahm data. The long chain limit reveals an asymmetric behavior transverse to the periodic direction, with the asymmetry becoming more pronounced at shorter separations. This analysis is motivated by a search for semiclassical finite temperature instantons in the 3D SU(2) Georgi-Glashow model, but it appears that in the periodic limit the instanton chains either have logarithmically divergent action or wash themselves out.Comment: 14 pages, 6 figures; v2 minor changes, published versio

Tacit collusion, firm asymmetries and numbers:evidence from EC merger cases

The purpose of this paper is to identify empirically the implicit structural model, especially the roles of size asymmetries and concentration, used by the European Commission to identify mergers with coordinated effects (i.e. collective dominance). Apart from its obvious policy-relevance, the paper is designed to shed empirical light on the conditions under which tacit collusion is most likely. We construct a database relating to 62 candidate mergers and find that, in the eyes of the Commission, tacit collusion in this context virtually never involves more than two firms and requires close symmetry in the market shares of the two firms

Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome:A PARDIE Study

Rationale: Few data exist to guide early adjunctive therapy use in pediatric acute respiratory distress syndrome (PARDS). Objectives: To describe contemporary use of adjunctive therapies for early PARDS as a framework for future investigations. Methods: This was a preplanned substudy of a prospective, international, cross-sectional observational study of children with PARDS from 100 centers over 10 study weeks. Measurements and Main Results: We investigated six adjunctive therapies for PARDS: continuous neuromuscular blockade, corticosteroids, inhaled nitric oxide (iNO), prone positioning, high-frequency oscillatory ventilation (HFOV), and extracorporeal membrane oxygenation. Almost half (45%) of children with PARDS received at least one therapy. Variability was noted in the median starting oxygenation index of each therapy; corticosteroids started at the lowest oxygenation index (13.0; interquartile range, 7.6–22.0) and HFOV at the highest (25.7; interquartile range, 16.7–37.3). Continuous neuromuscular blockade was the most common, used in 31%, followed by iNO (13%), corticosteroids (10%), prone positioning (10%), HFOV (9%), and extracorporeal membrane oxygenation (3%). Steroids, iNO, and HFOV were associated with comorbidities. Prone positioning and HFOV were more common in middle-income countries and less frequently used in North America. The use of multiple ancillary therapies increased over the first 3 days of PARDS, but there was not an easily identifiable pattern of combination or order of use. Conclusions: The contemporary description of prevalence, combinations of therapies, and oxygenation threshold for which the therapies are applied is important for design of future studies. Region of the world, income, and comorbidities influence adjunctive therapy use and are important variables to include in PARDS investigations

Predicting Mortality in Children With Pediatric Acute Respiratory Distress Syndrome:A Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology Study

OBJECTIVES: Pediatric acute respiratory distress syndrome is heterogeneous, with a paucity of risk stratification tools to assist with trial design. We aimed to develop and validate mortality prediction models for patients with pediatric acute respiratory distress syndrome. DESIGN: Leveraging additional data collection from a preplanned ancillary study (Version 1) of the multinational Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology study, we identified predictors of mortality. Separate models were built for the entire Version 1 cohort, for the cohort excluding neurologic deaths, for intubated subjects, and for intubated subjects excluding neurologic deaths. Models were externally validated in a cohort of intubated pediatric acute respiratory distress syndrome patients from the Children's Hospital of Philadelphia. SETTING: The derivation cohort represented 100 centers worldwide; the validation cohort was from Children's Hospital of Philadelphia. PATIENTS: There were 624 and 640 subjects in the derivation and validation cohorts, respectively. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The model for the full cohort included immunocompromised status, Pediatric Logistic Organ Dysfunction 2 score, day 0 vasopressor-inotrope score and fluid balance, and PaO2/FIO2 6 hours after pediatric acute respiratory distress syndrome onset. This model had good discrimination (area under the receiver operating characteristic curve 0.82), calibration, and internal validation. Models excluding neurologic deaths, for intubated subjects, and for intubated subjects excluding neurologic deaths also demonstrated good discrimination (all area under the receiver operating characteristic curve ≥ 0.84) and calibration. In the validation cohort, models for intubated pediatric acute respiratory distress syndrome (including and excluding neurologic deaths) had excellent discrimination (both area under the receiver operating characteristic curve ≥ 0.85), but poor calibration. After revision, the model for all intubated subjects remained miscalibrated, whereas the model excluding neurologic deaths showed perfect calibration. Mortality models also stratified ventilator-free days at 28 days in both derivation and validation cohorts. CONCLUSIONS: We describe predictive models for mortality in pediatric acute respiratory distress syndrome using readily available variables from day 0 of pediatric acute respiratory distress syndrome which outperform severity of illness scores and which demonstrate utility for composite outcomes such as ventilator-free days. Models can assist with risk stratification for clinical trials